Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti-PD-1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients.
Dan P ZandbergSerafettin ZenkinMurat AkPriyadarshini MamindlaVishal PeddagangireddyRonan HsiehJennifer L AndersonGreg M DelgoffeAshely MenkHeath D SkinnerUmamaheswar DuvvuriRobert L FerrisRivka R ColenPublished in: Head & neck (2024)
Radiomics accurately predicted the efficacy of IO and features of the TME in R/M HNSCC. Further study in a larger patient population is warranted.